COVID Related Research
We have recently launched three projects to conduct, analyze, and report on COVID-19 studies. Results from these studies ultimately could help pave the way toward better prevention and treatment for the deadly disease.
The Biostatistics Center Launches Three COVID-19 Projects
To improve public health and clinical practice by conducting transformative scientific research.
Our work has been recognized in reports to the United States White House and Congress.
Who We Are
The Biostatistics Center has a staff of approximately 120 with more than 40 biostatisticians and epidemiologists.
One of our projects, the MOMS Study, received the Society for Clinical Trials "Trial of the Year" Award.
Founded in 1972, the Biostatistics Center has a 46 year history of leadership in practice-changing clinical trials and biostatistical methodology research.
Our work has been cited in TIME Magazine’s “The Year in Medicine”.
Foster biostatistical science by developing and implementing innovative approaches for the design, conduct, analysis, and reporting of clinical research studies.
The Harvard Health Letter named one of our projects the #1 advance in medicine.
Research studies conducted by the Biostatistics Center have resulted in more than 60 publications in the New England Journal of Medicine.
We have received one of Clinical Research Forum’s Top Ten Awards.
The primary goal of the EDIC study is to assess the long-term benefits of early intensive blood glucose control on the future development of diabetes-related complications, in participants with type 1 diabetes originally enrolled in the Diabetes Control and Complications Trial (DCCT).
This study aims to conduct real-time syndromic disease surveillance and serosurveillance to estimate incidence and prevalence of COVID-19 among the general population and in subpopulations.
RISE includes 3 randomized clinical trials examining whether aggressive glucose lowering will lead to recovery of pancreas function (β-cell function) in adults and youth with impaired glucose tolerance (IGT) and early type 2 diabetes.
The main objective of this multi-center collaborative study is to evaluate sequencing (both whole exome sequencing [WES] and WGS) as a prenatal diagnostic tool in pregnancies with a structural anomaly and a negative or only non-causal karyotype/ chromosome microarray analysis (CMA).
The Lifestyle Interventions for Expectant Moms (LIFE-Moms) Consortium is designed to determine, in pregnant women with overweight or obesity, whether various behavioral and lifestyle interventions reduce excessive gestational weight gain and subsequent adverse maternal and neonatal outcomes and obesity in offspring.
This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care.
TODAY2 is the long term follow-up of the youth from TODAY, to track the progression of type 2 diabetes (T2D) and related comorbidities and complications in the TODAY cohort as they transition to young adulthood.
GRADE is a clinical trial comparing the effectiveness of 4 alternate randomly-assigned glucose-lowering therapies, in addition to metformin, in 5047 participants with type 2 diabetes over 4-7 years of follow-up to assess metabolic status, side effects, quality of life, beta cell function and micro- and macro-vascular complications.
The DPPOS aims to assess the long-term effects of interventions used in the Diabetes Prevention Program (DPP) on the development of type 2 diabetes and its complications.
Since 2009, the DC Cohort is a longitudinal research project designed to collect clinical data from HIV-infected outpatients receiving care at fifteen clinics in the District of Columbia.
This is a cohort study to compare maternal morbidity and mortality among pregnant and postpartum women with COVID-19 with those without the infection, and also to compare morbidity and mortality of this cohort to pre-pandemic deliveries.
The Antibacterial Resistance Leadership Group (ARLG) is an international cooperative clinical research network funded by NIAID to prioritize, design, and execute clinical research that will impact the prevention, diagnosis and treatment of infections caused by antibiotic-resistant bacteria.
The network is designed to focus on clinical questions in maternal-fetal medicine and obstetrics, particularly with respect to the continuing problem of preterm birth.
Biostatistics Center researchers advance the center’s mission of collaborative research by developing and implementing innovative practical methods for the design, execution, data monitoring, analyses and reporting of clinical studies. Current Biostatistics Center research includes the design and analyses of studies that focus on patient-focused outcome measures that integrate efficacy and safety, personalized treatment, cost-effectiveness analyses, response-adaptive randomization, and pragmatic evaluation of diagnostic technologies.
Education and Training
To help advance the field of biostatistics research, the Center faculty and staff are active in a wide array of educational and training initiatives, including teaching at professional meetings, publishing educational manuscripts and books, hosting training programs for students and scientific collaborators, and providing mentorship opportunities.